High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

Abstract excerpt

Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastric Cancer Management and Outcomes
• Share to Genetic factors in colorectal cancer
• Share to Viral-associated cancers and disorders